We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
- Authors
Galanis, Evanthia; Dooley, Katharine E.; Keith Anderson, S.; Kurokawa, Cheyne B.; Carrero, Xiomara W.; Uhm, Joon H.; Federspiel, Mark J.; Leontovich, Alexey A.; Aderca, Ileana; Viker, Kimberly B.; Hammack, Julie E.; Marks, Randolph S.; Robinson, Steven I.; Johnson, Derek R.; Kaufmann, Timothy J.; Buckner, Jan C.; Lachance, Daniel H.; Burns, Terry C.; Giannini, Caterina; Raghunathan, Aditya
- Abstract
Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA), was administered in recurrent GBM patients either at the resection cavity (Group A), or, intratumorally on day 1, followed by a second dose administered in the resection cavity after tumor resection on day 5 (Group B). A total of 22 patients received study treatment, 9 in Group A and 13 in Group B. Primary endpoint was safety and toxicity: treatment was well tolerated with no dose-limiting toxicity being observed up to the maximum feasible dose (2×107 TCID50). Median OS, a secondary endpoint, was 11.6 mo and one year survival was 45.5% comparing favorably with contemporary controls. Other secondary endpoints included assessment of viremia, MV replication and shedding, humoral and cellular immune response to the injected virus. A 22 interferon stimulated gene (ISG) diagonal linear discriminate analysis (DLDA) classification algorithm in a post-hoc analysis was found to be inversely (R = −0.6, p = 0.04) correlated with viral replication and tumor microenvironment remodeling including proinflammatory changes and CD8 + T cell infiltration in post treatment samples. This data supports that oncolytic MV derivatives warrant further clinical investigation and that an ISG-based DLDA algorithm can provide the basis for treatment personalization. Oncolytic measles virus (MV) vaccine strains have shown preclinical antitumor activity against glioblastoma (GBM). Here the authors report the results of a phase 1 trial of intratumoral administration of a MV strain engineered to express the carcinoembryonic antigen in patients with recurrent GBM including assessment of viral replication and proinflammatory remodeling of the treated tumors.
- Subjects
MEASLES virus; CARCINOEMBRYONIC antigen; GLIOBLASTOMA multiforme; CLASSIFICATION algorithms; ANTINEOPLASTIC agents; VIRAL replication
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-43076-7